In the absence of approved therapy, physicians mostly attempt to treat the pain of Chemotherapy-Induced Peripheral Neuropathy with oral antidepressants and anti-epileptics. After several weeks of treatment, those medicines can achieve limited pain reduction in some patients but tend to cause various side-effects : cardiovascular, neurological, psychological, neuromuscular or anticholinergic are the more frequent ones.

AlgoTx is developing the topical medicine ATX01 with an aim to demonstrate its efficacy on the pain and sensory symptoms of Chemotherapy-Induced Peripheral Neuropathy. ATX01’s pharmacological paradigm is that it would directly target the epidermis and dermis – where the damaged nerve fibers sit – and would avoid systemic absorption and its cascade of side-effects.

ATX01 completed Phase I Clinical Development and will enter Phase II in CIPN in 2022